Article thumbnail
Location of Repository

Kinase inhibitors for the treatment of inflammatory and autoimmune disorders

By Shripad S. Bhagwat


Drugs targeting inhibition of kinases for the treatment of inflammation and autoimmune disorders have become a major focus in the pharmaceutical and biotech industry. Multiple kinases from different pathways have been the targets of interest in this endeavor. This review describes some of the recent developments in the search for inhibitors of IKK2, Syk, Lck, and JAK3 kinases. It is anticipated that some of these compounds or newer inhibitors of these kinases will be approved for the treatment of rheumatoid arthritis, psoriasis, organ transplantation, and other autoimmune diseases

Topics: Review
Publisher: Springer Netherlands
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. A et al (2004) Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors.
  2. (2004). A novel series of potent and selective IKK2 inhibitors.
  3. (2008). A quantitative analysis of kinase inhibitor selectivity.
  4. (2006). A randomized, double-blind, placebo-controlled trial of 3 dose levels of CP690,550 versus placebo in the treatment of active rheumatoid arthritis (abstract L40). Presented at the American College of Rheumatology Annual Meeting,
  5. (2003). A selective IKK-2 inhibitor blocks NF-κB-dependent gene expression in interleukin-1b-stimulated synovial fibroblasts.
  6. Amit S et al (2000) High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-κB activation.
  7. (2003). An inhibitor of IκB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice.
  8. (2005). An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment.
  9. Audoly L et al (2008) Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis.
  10. Bhamra I et al (2007) N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics.
  11. Boeccia A et al (2007) Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-amine—a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.
  12. Burchat A et al (2007) Discovery of thienopyridines as Src-family selective Lck inhibitors.
  13. (2006). Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK.
  14. (2006). Development of N4,6-pyrimidine-N-alkyl-N’-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase.
  15. (2006). Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3. Bioorg Med Chem Lett 17:5633–5638
  16. (2003). Discovery and SAR of novel [1,6]naphthyridines as potent inhibitors of spleen tyrosine kinase (SYK).
  17. (2007). Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR.
  18. (2006). Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.
  19. (2006). Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
  20. (2007). Discovery of novel 2,3-diarylfuro[2,3-b]pyridine-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties.
  21. (2009). et al (2006) R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 319:998–1008 114 Purinergic Signalling
  22. et al (2007) CP-690,550 (CP), a JAK3 inhibitor, in de novo kidney transplant (KT) recipients: 6-month results of a phase 2 trial (abstract).
  23. Greissinger E et al (2003) AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-α in Jurkat leukemic cells.
  24. (2008). High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug Discov 7:391–397
  25. (2006). Identification of the Syk kinase inhibitor R112 by a human mast cell screen.
  26. (2007). IκB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges.
  27. KR et al (2003) BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice.
  28. Kuhn CF et al (2008) The specificity of JAK3 kinase inhibitors.
  29. Laufersweiler MJ et al (2006) The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck). Bioorg Med Chem Lett
  30. (2001). Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection.
  31. Lukas NWet al (2005) A selective novel low-molecular-weight inhibitor of IκB kinase-β (IKK-β) prevents pulmonary inflammation and slows broad anti-inflammatory activity.
  32. (2007). MAP kinase inhibitors in inflammation and autoimmune disorders.
  33. (2008). Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection.
  34. (2000). Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the γc-JAK3 signaling pathways as a model. Immunol Rev 178:39–48
  35. (2003). Potent small molecule inhibitors of spleen tyrosine kinase (Syk). Bioorg Med Chem Lett 13:3111–3114
  36. (2003). Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.
  37. Sakakibara S et al (2003) Discovery of novel and selective IKK-serine-threonine protein kinase inhibitors.
  38. (2007). Simplified staurosporine analogs as potent JAK3 inhibitors. Bioorg Med Chem Lett 17:326–331 Purinergic Signalling
  39. (2007). Synthesis and biological evaluation of 4-amino derivatives of benzimidazoquinoxaline, benzimidazoquinoline, and benzopyrazoloquinazoline as potent IKK inhibitors.
  40. (2007). Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for the treatment of acute ischemic stroke.
  41. (2007). Synthesis and structure-activity relationship of imidazo(1,2-a)thieno(3,2-e)pyrazines as IKK-β inhibitors.
  42. (2004). Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 2: improvement of in vitro activity.
  43. (2004). Synthesis and structure-activity relationships of novel IKK-β inhibitors. Part 3: orally active anti-inflammatory agents.
  44. (2004). Targeting Syk as a treatment for allergic and autoimmune disorders.
  45. (2006). The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck). Bioorg Med Chem Lett
  46. (2004). The novel JAK3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models.
  47. (2003). The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]-nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents.
  48. (2001). The small molecule IKK2 inhibitor SPC-839 is efficacious in an animal model of arthritis. A paper presented at ACR Annual Scientific Meeting,
  49. Toyoshima A et al (2005) Synthetic studies on novel Syk inhibitors. Part 1: synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives.
  50. Yet al (2000) Janus kinase 3 (Jak3) is essential for common cytokine receptor γ chain (γc) -dependent signaling: comparative analysis of γc,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.